Amarin taps suppliers for 'aggressive' launch

Amarin is getting all its manufacturing ducks in a row as it prepares for the debut of its new heart drug, AMR101. With positive data from two late-stage studies to support its approval app, Amarin ($AMRN) has forged new supply agreements to support an "aggressive" marketing campaign for the omega 3 drug, which is set to rival GlaxoSmithKline's Lovaza for market share. Report